Aurora and Ethypharm have again been selected by the French Direction Générale de la Santé (DGS) as exclusive suppliers of dried medical cannabis flowers for the end of the French therapeutic cannabis experimentation which has been extended until March 2024.
“We are delighted to have been selected once again to continue supplying high quality dried medical cannabis flower to the French pilot program. Driven by our goal to open the world to cannabis, Aurora continues to work hand-in-hand with government officials, doctors and pharmacists to reduce stigma and further develop medical markets across Europe,” said Dr. Axel Gille, President of Aurora Europe.
Aurora and Ethypharm signed an agreement to serve the French pilot program, led by the National Agency for the Safety of Medicines and Health Products (ANSM), in October 2020, leveraging the expertise of both parties.
Under the terms of this exclusive partnership, Aurora provides medical cannabis, along with EU GMP (Good Manufacturing Practice) compliant manufacturing and logistics support. Distribution and pharmacovigilance activities continue to be handled by Ethypharm Laboratories, the French commercial subsidiary of Ethypharm.
As part of the trial extension, the DGS opened a tender for the supply of medical cannabis in January 2023. In March, Aurora Europe and Ethypharm were selected to continue supplying medical cannabis produced according to European GMP standards to patients included in the study.
As committed partners, Ethypharm and Aurora Europe reaffirm their commitment to patients and healthcare professionals to improve the status and accessibility of medical cannabis in Europe.
“By planning to make Aurora’s pharmaceutical-grade medical cannabis available in France, we want to strengthen our expertise in central nervous system pathologies, and in particular in the treatment of pain. We are proud to move forward with the French health authorities and health professionals in this experimentation which, we hope, will show the interest of the use of medical cannabis to relieve French patients of certain symptoms such as pain “, declared Frédéric Arnal, Managing Director of Ethypharm Laboratories.
